tbuckley/cabot-search huggingface dataset:
M. COVENTRY (Ed.) The 1981 Year Book of Orthopedics
Authors: B. Helal
Journal: British Journal of Sports Medicine (1982)

90capacity.However, some of the patients do not respond and are commonly treated with local injection of steroids and local anaesthetics.Paediatrics, tumours and infections completed the disease sections.Chapters on Regional Surveys follow -the spine, hip, knee, foot and ankle, hand and wrist, shoulder and elbow are succeeded by joint replacement and fractures.The book ends with a chapter on sports injuries.Ski, wrestling and karate injuries are described, also pack palsy in hikers due to nerve compression and iliotibial friction syndrome in runners.Breaststroker's knee is a good paper with an excellent motion analysis and analysis of the stress involved with modifications necessary to relieve the specific problems.There is a good index, and all chapters are well illustrated.This is an Orthopaedists book -full of interest -a book to browse through at leisure.
Clinical Judgment and Sickle Cell Disease
Authors: Graham R. Serjeant
Journal: New England Journal of Medicine (1993)

Physicians in developing countries who treat patients with sickle cell disease have traditionally relied heavily on clinical judgment. The combination of the high prevalence of the disorder and the limited diagnostic and therapeutic facilities available means that only treatments based on incontestable clinical evidence are feasible. When a patient is febrile or markedly anemic, treatment has to be largely empirical, with reliance on antibiotics or blood transfusion. Clinical compromises are inevitable, and doctors face the harsh discipline of deciding which treatments are really justified by the available data. By contrast, doctors working in more privileged circumstances can afford to be . . .
970-1 Adverse Prognosis of an Unsuccessful Mitral Valve Repair Immediately Followed by Valve Replacement: Value of Echocardiography
Authors: Irene M. Hellemans, Els G. Pieper, Anita C.J. Ravelli, Johannes P.M. Hamer, Wybren Jaarsma, Emile C. Cheriex, Henry A. van Swieten, Cathinka H. Peels, Jan G.P. Tyssen, Cees A. Visser
Journal: Journal of the American College of Cardiology (1995)
WDR62 is associated with the spindle pole and is mutated in human microcephaly
Authors: Adeline K Nicholas, Maryam Khurshid, Julie Désir, Ofélia P Carvalho, James J Cox, Gemma Thornton, Rizwana Kausar, Muhammad Ansar, Wasim Ahmad, Alain Verloes, Sandrine Passemard, Jean-Paul Misson, Susan Lindsay, Fanni Gergely, William B Dobyns, Emma Roberts, Marc Abramowicz, C Geoffrey Woods
Journal: Nature Genetics (2010)
Appropriate statistical test in comparative ulcer healing studies.
Authors: E Boyd, I N Marks
Journal: Gut (1985)

Age-related memory impairment (AMI) is a critical and debilitating phenotype of brain aging, but its underlying molecular mechanisms are largely unknown. In <i>Drosophila</i>, AMI is highly correlated with PKA activity in the mushroom bodies, neural centers essential for forming associative olfactory memories. Heterozygous mutations in <i>DC0</i> (<i>DC0</i>/+), which encodes the major catalytic subunit of PKA (PKAc), significantly suppress AMI, while overexpression of a <i>DC0</i> transgene (<i>DC0</i><sup>+</sup>) impairs memory and occludes AMI. PKA activity does not increase upon aging, and it is not clear whether AMI is caused by continual PKA activity throughout aging or by an acute increase in PKA signaling at old ages. Likewise, it is not clear whether AMI can be ameliorated by acute interventions at old ages or whether continuous intervention throughout aging is necessary. We show here that an acute increase in PKA activity at old ages is sufficient to restore normal AMI in <i>DC0</i>/+ flies. Conversely, acute expression of a PKA inhibitory peptide at old ages is sufficient to reverse AMI in a wild-type background. These results indicate that AMI in <i>Drosophila</i> is caused by an age-dependent change in PKA-dependent signaling that can be reversed by acute interventions at old ages.
Pathology of the Stomach and Duodenum
Authors: Milton G. Bohrod
Journal: JAMA (1989)

Textbooks about the digestive tract usually cover the entire tract; this one is limited to the stomach and duodenum. Since Dr Enterline is also one of the authors of<i>Pathology of the Esophagus</i>, we may perhaps expect an additional volume on the remainder of the tract. There is no particular objection to this— it may even be handy, unbulky—except for what it does to the price. The cost of scientific books has already escalated to portentous heights, often (in my possibly erroneous opinion) to unjustified heights. This results in the sale of fewer books, which of course calls for further increases of price and thus denies the books to many of our younger colleagues, the very ones who need them most. The present text is very clearly and succinctly written. Clarity of language and the absence of unnecessary jargon explain, no doubt, why so much information is crowded into so
Abstract 2245: Mechanism of replicative senescence induced by SNF5 loss
Authors: Darmood Wei, HoYoon Chung, Dennis A. Simpson, William K. Kaufmann, Bernard E. Weissman
Journal: Cancer Research (2014)

Abstract Cellular senescence was initially described as the phenomenon by which normal diploid cells cease to divide after reaching the Hayflick limit. However, with the identification of replicative senescence, other inducers of this process have appeared in the literature including oncogene induced senescence (OIS). Of interest, different oncogenes can initiate OIS through alternative pathways e.g. HRAS (G12V) and BRAF (V600E) that effect senescence through p16 dependent and p16 independent pathways, respectively. Alternatively, loss of tumor suppressor gene function can also induce senescence. In malignant rhabdoid tumors (MRTs), SNF5 behaves as a tumor suppressor and its re-expression in MRT cell lines results in growth arrest via the RB pathway. Paradoxically, when we knocked out SNF5 in normal human fibroblasts (NHF-1), we also observed senescence. We therefore hypothesize that perturbation of the SWI/SNF complex (e.g. knocking down SNF5) results in cellular senescence in most normal tissues. This suggests an epigenetic mechanism of senescence occurring through a p16 independent pathway, as previous publications have demonstrated a critical role for SNF5 in p16 expression. Additionally, in BRAF induced senescence, changes in levels of CD44, phospho-MEK1/2, and p16 are observed. However, we do not find these changes during SNF5 loss. Our findings suggest a relationship between SWI/SNF's chromatin remodeling activity and the regulation of cellular senescence. Importantly, our studies will identify the key signaling pathways that allow MRTs to escape cellular senescence after SNF5 loss. These results will further elucidate the role of SNF5 loss in MRT development and provide new targets for clinical intervention. Acknowledgement: We thank the members of the Weissman lab for their help, advice, and support and R01CA91048 (B.E.W.) , T32ES007126 (D.W.), UNC Dissertation Completion Fellowship (D.W.) for financial support. Citation Format: Darmood Wei, HoYoon Chung, Dennis A. Simpson, William K. Kaufmann, Bernard E. Weissman. Mechanism of replicative senescence induced by SNF5 loss. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 2245. doi:10.1158/1538-7445.AM2014-2245
Streptomycin, I.N.H. and thiacetazone
Authors: F. I. Tovey, N. Setty, R. M. Barton
Journal: BMJ (1967)

emerged from large studies in Texas9 and South Africa."`'12Altogether it seems unlikely that enteroviruses or adenoviruses are significant causes of uncomplicated diarrhoeal disease.Routine virological investigation by present techniques of stools from diarrhoeal patients is an unrewarding diver- sion of effort.Perhaps when the technical trick of demonstrating hepatitis virus has been discovered a new group of agents may be found responsible for that large majority of diarrhoeal illnesses in which neither viro- logical nor bacteriological tests are currently successful.-Weare, etc.,
Asbestos Exposure, Smoking, and Neoplasia
Authors: Irving J. Selikoff
Journal: JAMA (1968)

Asbestos insulation workers, as a group, have a high risk of dying of bronchogenic carcinoma (about seven or eight times expected). We have observed 370 such workmen from Jan 1, 1963 to April 30, 1967. Our findings indicate that asbestos exposure alone is not the entire explanation. Of 87 noncigarette smokers, none died of bronchogenic carcinoma. Of 283 workmen with a history of regular cigarette smoking, 24 died of bronchogenic carcinoma, although only three were expected to die of this disease. Calculations suggest that asbestos workers who smoke have about 92 times the risk of dying of bronchogenic carcinoma as men who neither work with asbestos nor smoke cigarettes. We conclude that asbestos exposure should be minimized, that asbestos workers who do not smoke should never start, and that those now smoking should stop immediately.
Labour pledges to reform libel laws in England and Wales
Authors: C. Dyer
Journal: BMJ (2010)

The libel laws of England and Wales will be reformed to stem “libel tourism” and curb the law’s chilling effect on free expression if Labour forms the next government, justice secretary Jack Straw has pledged.

Mr Straw promised a new bill in the next parliament if Labour wins the forthcoming general election, expected in May.

However, he promised only to “give consideration to” the most important measure, a possible statutory public interest to protect responsible journalism from the chilling effect of possible legal action.

Announcing the proposals in a written statement to parliament, he said he would ask the civil procedure rules committee to …
Baroreceptor Function in Hypertensive and Normotensive Patients with Uremia.
Authors: J. M. Lazarus
Journal: Annals of Internal Medicine (1972)

Meeting Abstracts1 May 1972Baroreceptor Function in Hypertensive and Normotensive Patients with Uremia.J. M. Lazarus, M.D., C. L. Hampers, M.D., J. P. Merrill, M.D.J. M. Lazarus, M.D.Search for more papers by this author, C. L. Hampers, M.D.Search for more papers by this author, J. P. Merrill, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-76-5-875_1 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptA group of patients were on hemodialysis with persistent hypertension despite maximum ultrafiltration and bilateral nephrectomy. In a pilot study of 140 hemodialysis patients, an increased frequency and severity of posturalhypotension was found inhypertensive uremic patients and suggests an abnormality in the baroreceptor mechanism. To further evaluate a "resetting" of the baroreceptor mechanism the effects of standing and drug-induced blood pressure changes were serially studied in four normotensive and nine hypertensive (> 150/90 mm Hg) patients before and after nephrectomy. Baroreceptor function was evaluated by the pulse response to elevation and lowering of blood pressure with angiotensin and... This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAuthors: J. M. Lazarus, M.D.; C. L. Hampers, M.D.; J. P. Merrill, M.D.Affiliations: Boston, Mass. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byHemodynamic lesions in hypertension 1 May 1972Volume 76, Issue 5Page: 875-875KeywordsBlood pressureDrugsHeart rateHypertensionHypotensionNephrectomyPilot studiesUltrafiltration ePublished: 1 December 2008 Issue Published: 1 May 1972 PDF downloadLoading ...
Medical-Legal Aspects of Curbside Consultation-Reply
Authors: Farrin A. Manian
Journal: JAMA (1996)

<h3>In Reply.</h3> —We appreciate the comments of Dr Fox and share his concern regarding the potential for the current managed care environment to redefine physicians' duty of care to include situations outside the traditional physician-patient relationship. Specifically, we also are concerned about the possibility that a consultant under contract with a managed care organization may be subject to litigation by giving informal advice to another participating physician regarding the care of a patient enrolled in the same plan. Fortunately, the circumstances of the case cited by Fox<sup>1</sup>were sufficiently different than those surrounding most curbside consultations that the verdict in favor of the plaintiff cannot be invoked to encourage future litigation involving consultants who give informal advice to their colleagues. First, the defendant was the de facto assigned primary caregiver (not a consultant) for the plaintiff under the health care plan agreement. Second, as the gatekeeper, the defendant implicitly assumed major
Embolic event rates after direct current cardioversion in patients with atrial fibrillation and ineffective anticoagulation: results of the Ludwigshafen observational atrial fibrillation study
Authors: Karlheinz Seidl, Monika Rameken, Margit Vater, Harald Schwacke, Andreas Brandt, Caroline Bergmeier, Ralf Zahn, Jochen Senges
Journal: Journal of the American College of Cardiology (2002)
Digital Computer Analyzed Sleep and Resting EEG During Haloperidol Treatment
Authors: TURAN M. ITIL, PATRICK GANNON, WILLIAM HSU, HELEN KLINGENBERG
Journal: American Journal of Psychiatry (1970)

The authors studied the effects of haloperidol on resting and all-night sleep EEGs of chronic schizophrenic patients. There was a decrease in slow waves and an increase in fast activity during resting and sleep EEGs as well as a decrease in the time spent in deep sleep stages during sleep. The findings support the hypothesis that compounds that are most effective with chronic schizophrenic patients have both central inhibitory and stimulating components.
Autoantibody reactive with three classes of RNA polymerases in sera from patients with systemic sclerosis.
Authors: M Kuwana, J Kaburaki, T Mimori, T Tojo, M Homma
Journal: Journal of Clinical Investigation (1993)

We have identified a novel autoantibody reactive with all three classes of RNA polymerases, well-characterized nuclear enzymes, in sera from patients with systemic sclerosis (SSc). After incubation with [35S]methionine-labeled HeLa cell extracts, 14 of 275 SSc sera immunoprecipitated 12 or 14 proteins with similar molecular weights as those of several subunit proteins of eukaryotic RNA polymerases I, II, and III. Purified IgG from these two types of sera inhibited RNA transcription catalyzed by RNA polymerases I, II, and III in vitro. Immunoblot analysis using RNA polymerase-enriched fraction showed that the majority of these sera reacted with 42- or 25-kD protein. Anti-RNA polymerase antibody was highly specific to SSc, especially to diffuse cutaneous SSc. Clinical features associated with this antibody included a high frequency of heart and kidney involvement and a poor survival rate at 5 yr after first visit. These findings indicate that the autoantibody to three classes of RNA polymerases is a new marker for a unique subset of diffuse cutaneous SSc.
Abstract 3891: Reduced tumor formation by forced expression of cyclin-dependent kinase 6 in mouse epidermis
Authors: Xian Wang, Christopher Sistrunk, Marcelo Rodriguez-Puebla
Journal: Cancer Research (2010)

Abstract The Cyclin-Dependent kinases (CDKs) are a family of essential serine-threonine kinases that are cell cycle regulated by association with cyclins at specific time-points during the cell cycle. Specifically, D-type cyclins form complexes and activate CDK4 and CDK6. We have previously determined that overexpression of CDK4 in mouse epidermis increases malignant progression in chemically induced skin tumors. In order to study the role of CDK6 in squamous epithelial tissues, we generated transgenic mice overexpressing CDK6, driven by the regulatory sequence of the keratin 5 promoter (K5CDK6). Keratinocytes from K5CDK6 mice have similar levels of proliferation compared to wild type mice, however, contrary to the role of CDK4 in mouse skin tumorigenesis, forced expression of CDK6 results in strong reduction of the multiplicity (papillomas per mouse) and incidence of skin tumors. Tumors derived from K5CDK6 or the wild type sibling show no histological differences nor changes in the rate of malignant progression, suggesting that CDK6 expression affects early stages of skin carcinogenesis. Our previous results have also shown that CDK6 preferentially binds to cyclin D3, which overexpression also decreases tumor development in mouse epidermis. Interestingly, lack of Cyclin D1 produces similar phenotype upon chemical carcinogenesis treatment. Thus, we hypothesize that overexpression of Cyclin D3 or CDK6 in a Cyclin D1-null background should synergize with the reduced tumor development previously observed in cyclin D1-null mice. As expected, a lower number of tumors were found in K5-cyclin D3/cyclin D1−/− compound mice compared to cyclin D1−/− siblings. Thus, we hypothesized that the reduced tumor development observed in these mice is a result of the CDK6/Cyclin D3 complex activity. Consequently, K5-CDK6/cyclin D3−/− compound mice are being generated to investigate whether CDK6-associated tumor inhibition depends on cyclin D3 expression. Only in few cases, CDK6 has been associated with tumorigenesis as compared to CDK4 and CDK2, in particular, no association of CDK6 with epidermal tumors has been reported so far. We propose that CDK6/cyclin D3 complexes play an important role in maintaining normal epidermal homeostasis. Therefore we speculate that upregulation of one or both of its components will block tumor development which could be use as a therapeutic approach. Supported by NIH grant CA116328. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 3891.
Frail Older Adults and Palliative Care—Reply
Authors: Kenneth Boockvar, Diane Meier
Journal: JAMA (2007)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Direct and indirect effects of microstructured titanium substrates on the induction of mesenchymal stem cell differentiation towards the osteoblast lineage
Authors: Rene Olivares-Navarrete, Sharon L. Hyzy, Daphne L. Hutton, Christopher P. Erdman, Marco Wieland, Barbara D. Boyan, Zvi Schwartz
Journal: Biomaterials (2010)
Rofecoxib and Cardiovascular Adverse Events in Adjuvant Treatment of Colorectal Cancer
Authors: David J. Kerr, Janet A. Dunn, Michael J. Langman, Justine L. Smith, Rachel S.J. Midgley, Andrew Stanley, Joanne C. Stokes, Patrick Julier, Claire Iveson, Ravi Duvvuri, Christopher C. McConkey
Journal: New England Journal of Medicine (2007)

Selective cyclooxygenase inhibitors may retard the progression of cancer, but they have enhanced thrombotic potential. We report on cardiovascular adverse events in patients receiving rofecoxib to reduce rates of recurrence of colorectal cancer.All serious adverse events that were cardiovascular thrombotic events were reviewed in 2434 patients with stage II or III colorectal cancer participating in a randomized, placebo-controlled trial of rofecoxib, 25 mg daily, started after potentially curative tumor resection and chemotherapy or radiotherapy as indicated. The trial was terminated prematurely owing to worldwide withdrawal of rofecoxib. To examine possible persistent risks, we examined cardiovascular thrombotic events reported up to 24 months after the trial was closed.The median duration of active treatment was 7.4 months. The 1167 patients receiving rofecoxib and the 1160 patients receiving placebo were well matched, with a median follow-up period of 33.0 months (interquartile range, 27.6 to 40.1) and 33.4 months (27.7 to 40.4), respectively. Of the 23 confirmed cardiovascular thrombotic events, 16 occurred in the rofecoxib group during or within 14 days after the treatment period, with an estimated relative risk of 2.66 (from the Cox proportional-hazards model; 95% confidence interval [CI], 1.03 to 6.86; P=0.04). Analysis of the Antiplatelet Trialists' Collaboration end point (the combined incidence of death from cardiovascular, hemorrhagic, and unknown causes; of nonfatal myocardial infarction; and of nonfatal ischemic and hemorrhagic stroke) gave an unadjusted relative risk of 1.60 (95% CI, 0.57 to 4.51; P=0.37). Fourteen more cardiovascular thrombotic events, six in the rofecoxib group, were reported within the 2 years after trial closure, with an overall unadjusted relative risk of 1.50 (95% CI, 0.76 to 2.94; P=0.24). Four patients in the rofecoxib group and two in the placebo group died from thrombotic causes during or within 14 days after the treatment period, and during the follow-up period, one patient in the rofecoxib group and five patients in the placebo group died from cardiovascular causes.Rofecoxib therapy was associated with an increased frequency of adverse cardiovascular events among patients with a median study treatment of 7.4 months' duration. (Current Controlled Trials number, ISRCTN98278138 [controlled-trials.com].).
FDA adds "black box" warning label to fluoroquinolone antibiotics
Authors: J. H. Tanne
Journal: BMJ (2008)

The US Food and Drug Administration has told manufacturers of fluoroquinolones to warn doctors and patients of the raised risk of tendinitis and tendon rupture. The “black box” warning, the most stringent, must be added to drug labels and prescribing information, and manufacturers must also develop a treatment guide for patients.

These measures, the FDA said on 8 July, would strengthen the existing warnings in the prescribing information for fluoroquinolones. The warnings apply to tablets, capsules, and injectable formulations for systemic use but not to ophthalmic or otic formulations. …
Human Lymphocytes Bear Membrane Receptors for C3b and C3d
Authors: Aline Eden, Gary W. Miller, Victor Nussenzweig
Journal: Journal of Clinical Investigation (1973)

Human peripheral blood lymphocytes have membrane receptors for EAC43b (sheep erythrocytes sensitized with antibody and complement) and also for EAC43d, obtained by treating EAC43b with C3b inactivator. Human granulocytes bind only EAC43b, C3 fragments obtained by limited trypsin digestion of purified human C3 display both C3b and C3d sites, since they inhibit rosette formation of lymphocytes with EAC43b and EAC43d. These findings raise the possibility that C3b and C3d receptor sites may be selectively distributed among normal subpopulations of B lymphocytes as well as among leukemic leukocytes.